FSPM (FusionPharm, Inc., PNK) rises 9,900% Jan 24, 2026: monitor volume
FSPM stock moved sharply in market hours on Jan 24, 2026 after the share price jumped to $0.00010, a one-day increase of 9,900.00% from the prior close. The ticker FSPM (FusionPharm, Inc.) on the PNK exchange saw volume of 300 shares versus an average of 2,586, producing a large relative volume spike. Traders flagged the move in the Healthcare sector, where FusionPharm operates in Medical – Pharmaceuticals, and the action appears driven by low-float dynamics rather than company fundamentals. We examine the price action, metrics, technicals, and Meyka AI forecasts to frame short-term trading risks and potential upside for investors.
FSPM stock market snapshot
FSPM (FusionPharm, Inc.) trades on the PNK exchange in the United States and closed at $0.00010 during market hours on Jan 24, 2026. Market cap is listed at $1,259.00 with 12,591,545 shares outstanding and a daily volume of 300 versus an average volume of 2,586. The one-day percentage change reported is 9,900.00%, with the intraday range showing a narrow band at $0.00010. This snapshot highlights extreme price sensitivity given the tiny quote size and thin liquidity.
Why the FSPM stock price moved
The price move for FSPM stock appears linked to low liquidity and a tiny previous close of $0.00001, magnifying small buy orders into large percentage gains. There is no concurrent earnings or corporate news tied to FusionPharm, Inc.’s PharmPod product line; public filings and the company website show ongoing cultivation container sales but no new material disclosure. Given the mismatch between volume and average volume, short-term traders likely drove the spike rather than a change in fundamentals.
Fundamentals and valuation for FSPM stock
FusionPharm, Inc. reports EPS of -0.147 and no reported P/E ratio, reflecting current losses and limited financial disclosure. The company lists four full-time employees and focuses on indoor plant cultivation containers under the PharmPod brand. With a market cap of $1,259.00 and limited liquidity, standard valuation ratios are of limited use; investors should treat any implied valuation as highly uncertain. The company is in the Healthcare sector and Medical – Pharmaceuticals industry, but its revenue base and scale remain small.
Technicals, momentum and Meyka AI grade for FSPM stock
Technical indicators for FSPM show neutral momentum with RSI around 51.85 and an ADX at 50.58, indicating a strong trend but distorted by sparse pricing data. On-chain volume metrics show OBV deep negative and MFI elevated at 93.42, signaling overbought readings in a thin market. Meyka AI rates FSPM with a score out of 100: 58.81 | Grade: C+ | Suggestion: HOLD. This grade factors in S&P 500 comparison, sector and industry metrics, financial growth, key metrics, forecasts, and analyst consensus. These grades are informational only and not investment advice.
FSPM stock outlook and Meyka AI forecast
Meyka AI’s forecast model projects a 1-year target of $0.00051 for FSPM stock, a 3-year target of $0.00074, and a 5-year level near $0.00086. Compared with the current quote of $0.00010, the 1-year projection implies an upside of roughly 410.18%. Forecasts are model-based projections and not guarantees. Given the thin trading and limited public financials, any forecast should be weighed against high volatility and execution risk.
Risks and trading considerations for FSPM stock
Key risks for FSPM stock include extreme liquidity constraints, limited public financial disclosure, and the potential for wide bid-ask spreads on the PNK exchange. The company has small scale with four employees and a niche product line, which increases operational risk. For traders, position sizing and exit plans are critical; institutional coverage and analyst price targets are absent, raising reliance on short-term technical signals rather than fundamentals.
Final Thoughts
FSPM stock shows an outsized one-day move to $0.00010 on Jan 24, 2026 driven mainly by thin liquidity and relative volume spikes. FusionPharm, Inc. reports EPS of -0.147 and a market cap of $1,259.00, underscoring limited scale. Meyka AI’s forecast model projects a 1-year target of $0.00051, implying an estimated upside of 410.18% versus the current price; forecasts are model-based projections and not guarantees. Given the lack of material corporate news and the high noise in low-priced tickers, the market action reads as speculative. Investors and traders should treat FSPM as high risk, use tight position controls, and consult multiple sources before placing capital. For a live quote and trading data, see our FusionPharm profile on Meyka and market coverage on industry sites for verification. source FusionPharm on Meyka
FAQs
What caused the FSPM stock jump on Jan 24, 2026?
The move appears driven by very low liquidity and a small prior close, turning modest buy demand into a 9,900.00% one-day rise. There was no major earnings or corporate press release tied to FusionPharm, Inc. during the move.
What is Meyka AI’s view on FSPM stock?
Meyka AI rates FSPM 58.81 (C+) | HOLD and projects a 1-year model target of $0.00051. The platform highlights high volatility and limited financial disclosure as key cautions.
Is FSPM stock a good long-term investment?
Given FusionPharm’s small scale, negative EPS of -0.147, and thin trading, FSPM stock presents high risk for long-term investors. Consider diversification and strict risk limits before allocating capital.
What price target does Meyka AI forecast for FSPM stock?
Meyka AI’s model projects a 1-year target of $0.00051, a 3-year target of $0.00074, and a 5-year level near $0.00086. These are model outputs, not guarantees.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
